STRO vs. CHRS, ADVM, XFOR, CMPX, FENC, BDTX, ELEV, ABOS, IPHA, and OPT
Should you be buying Sutro Biopharma stock or one of its competitors? The main competitors of Sutro Biopharma include Coherus BioSciences (CHRS), Adverum Biotechnologies (ADVM), X4 Pharmaceuticals (XFOR), Compass Therapeutics (CMPX), Fennec Pharmaceuticals (FENC), Black Diamond Therapeutics (BDTX), Elevation Oncology (ELEV), Acumen Pharmaceuticals (ABOS), Innate Pharma (IPHA), and Opthea (OPT). These companies are all part of the "biological products, except diagnostic" industry.
Sutro Biopharma (NASDAQ:STRO) and Coherus BioSciences (NASDAQ:CHRS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, media sentiment, community ranking, dividends, valuation and earnings.
97.0% of Sutro Biopharma shares are owned by institutional investors. Comparatively, 72.8% of Coherus BioSciences shares are owned by institutional investors. 6.9% of Sutro Biopharma shares are owned by insiders. Comparatively, 11.0% of Coherus BioSciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Sutro Biopharma has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500. Comparatively, Coherus BioSciences has a beta of 0.54, meaning that its share price is 46% less volatile than the S&P 500.
Sutro Biopharma has higher earnings, but lower revenue than Coherus BioSciences. Sutro Biopharma is trading at a lower price-to-earnings ratio than Coherus BioSciences, indicating that it is currently the more affordable of the two stocks.
In the previous week, Sutro Biopharma had 2 more articles in the media than Coherus BioSciences. MarketBeat recorded 2 mentions for Sutro Biopharma and 0 mentions for Coherus BioSciences. Sutro Biopharma's average media sentiment score of 0.67 beat Coherus BioSciences' score of 0.00 indicating that Sutro Biopharma is being referred to more favorably in the media.
Coherus BioSciences received 316 more outperform votes than Sutro Biopharma when rated by MarketBeat users. Likewise, 64.97% of users gave Coherus BioSciences an outperform vote while only 63.78% of users gave Sutro Biopharma an outperform vote.
Sutro Biopharma has a net margin of -69.47% compared to Coherus BioSciences' net margin of -92.48%. Coherus BioSciences' return on equity of 0.00% beat Sutro Biopharma's return on equity.
Sutro Biopharma presently has a consensus target price of $12.57, suggesting a potential upside of 227.38%. Coherus BioSciences has a consensus target price of $9.29, suggesting a potential upside of 320.17%. Given Coherus BioSciences' higher probable upside, analysts plainly believe Coherus BioSciences is more favorable than Sutro Biopharma.
Summary
Sutro Biopharma beats Coherus BioSciences on 11 of the 18 factors compared between the two stocks.
Get Sutro Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for STRO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding STRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sutro Biopharma Competitors List
Related Companies and Tools
